Osteoporosis and venous thromboembolism: A retrospective cohort study in the UK General Practice Research Database

Osteoporosis International

Volumn 21, Issue 7, 2010, Pages 1181-1187

  Breart, G ^a   Cooper, C ^b,c   Meyer, O ^d   Speirs, C ^e   Deltour, N ^f   Reginster, J Y ^g  

^a HÔPITAL TENON   (France)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d BICHAT HOSPITAL   (France)

^e EPSOM GENERAL HOSPITAL   (United Kingdom)

^f INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^g UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Alendronate sodium; GPRD; Osteoporosis; Risk factors; Strontium ranelate; Venous thromboembolism

Indexed keywords

ALENDRONIC ACID; STRONTIUM RANELATE; BONE DENSITY CONSERVATION AGENT; ORGANOMETALLIC COMPOUND; THIOPHENE DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENERAL PRACTICE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; OSTEOPOROSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; UNITED KINGDOM; VENOUS THROMBOEMBOLISM; EPIDEMIOLOGY; MIDDLE AGED; POSTMENOPAUSE OSTEOPOROSIS;

AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; EPIDEMIOLOGIC METHODS; FEMALE; GREAT BRITAIN; HUMANS; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; THIOPHENES; VENOUS THROMBOEMBOLISM;

EID: 78149459093     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-009-1050-7     Document Type: Article

References (40)

1. Spencer FA, Emery C, Lessard D, Anderson F, Emani S, Aragam J, Becker RC, Goldberg RJ (2006) The Worcester venous thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 21:722-727
2. Rosendaal FR, Van Hylckama Vlieg A, Doggen CJ (2007) Venous thrombosis in the elderly. J Thromb Haemost 5(Suppl 1):310-317
3. Silverstein RL, Bauer KA, Cushman M, Esmon CT, Ershler WB, Tracy RP (2007) Venous thrombosis in the elderly: more questions than answers. Blood 110:3097-3101
4. Kuehn BM (2008) New tool measures 10-year fracture risk. JAMA 299:1651-1652
5. Guessous I, Cornuz J, Ruffieux C, Burckhardt P, Krieg MA (2008) Osteoporotic fracture risk in elderly women: estimation with quantitative heel US and clinical risk factors. Radiology 248:179-184
6. Cheung AM, Detsky AS (2008) Osteoporosis and fractures: missing the bridge? JAMA 299:1468-1470
7. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399-428
8. Maclaughlin EJ, Sleeper RB, McNatty D, Raehl CL (2006) Management of age-related osteoporosis and prevention of associated fractures. Ther Clin Risk Manag 2:281-295
9. Roux C (2008) Strontium ranelate: short- and long-term benefits for post-menopausal women with osteoporosis. Rheumatology (Oxford) 47(Suppl 4):iv20-iv22
10. Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE (2004) Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int 15:767-778
11. EMEA (2008) SPC: summary product characteristics (EMEA 2008)
12. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM (1996) Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 348:981-983
13. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189-2197
14. Vickers MR, MacLennan AH, Lawton B, Ford D, Martin J, Meredith SK, DeStavola BL, Rose S, Dowell A, Wilkes HC, Darbyshire JH, Meade TW (2007) Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ 335:239
15. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125-137
16. Jick H, Jick SS, Derby LE (1991) Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 302:766-768
17. Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigomez A, Meier CR, Schlienger RG, Black C, Jick H (2003) Validity of the general practice research database. Pharmacotherapy 23:686-689
18. Lawrenson R, Todd JC, Leydon GM, Williams TJ, Farmer RD (2000) Validation of the diagnosis of venous thromboembolism in general practice database studies. Br J Clin Pharmacol 49:591-596
19. Ray WA (2003) Evaluating medication effects outside of clinical trials: new user designs. Am J Epidemiol 158:915-920
20. Grosso A, Douglas I, Hingorani A, MacAllister R, Smeeth L (2008) Post-marketing assessment of the safety of strontium ranelate: a novel case-only approach to the early detection of adverse drug reactions. Br J Clin Pharmacol 66:689-694
21. Farrington CP (2004) Control without separate controls: evaluation of vaccine safety using case-only methods. Vaccine 22:2064-2070
22. Decensi A, Maisonneuve P, Rotmensz N, Bettega D, Costa A, Sacchini V, Salvioni A, Travaglini R, Oliviero P, D'Aiuto G, Gulisano M, Gucciardo G, del Turco MR, Pizzichetta MA, Conforti S, Bonanni B, Boyle P, Veronesi U (2005) Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation 111:650-656
23. Heit JA, Silverstein MD, Mohr DN, Petterson TM, Lohse CM, O'Fallon WM, Melton LJ III (2001) The epidemiology of venous thromboembolism in the community. Thromb Haemost 86:452-463
24. Scottish Intercollegiate Guidelines Network (2002) Prophylaxis of Venous Thromboembolism: a national clinical guideline. SIGN, Edinburgh
25. National Institute for Clinical Excellence (2007) Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in in-patients undergoing surgery. NICE Clinical guideline
26. Huerta C, Johansson S, Wallander MA, Garcia Rodriguez LA (2007) Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 167:935-943
27. Fimognari FL, Repetto L, Moro L, Gianni W, Incalzi RA (2005) Age, cancer, and the risk of venous thromboembolism. Crit Rev Oncol Hematol 55:207-212
28. Kyrle PA, Eichinger S (2005) Venous thromboembolism in men and women. J Men's Health & Gender 2:302-308
29. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J (2007) Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 5:692-699
30. White RH (2003) The epidemiology of venous thromboembolism. Circulation 107:I4-I8
31. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158:585-593
32. Oger E (2000) Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 83:657-660
33. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333-340
34. Melton LJ III (2000) Who has osteoporosis? A conflict between clinical and public health perspectives. J Bone Miner Res 15:2309-2314
35. Rosendaal FR (1999) Risk factors for venous thrombotic disease. Thromb Haemost 82:610-619
36. Kwong LM (2004) Hip fracture and venous thromboembolism in the elderly. J Surg Orthop Adv 13:139-148
37. Halil M, Cankurtaran M, Yavuz BB, Ulger Z, Piskinpasa S, Gedik A, Haznedaroglu IC, Kirazli S, Ariogul S (2007) Short-term hemostatic safety of strontium ranelate treatment in elderly women with osteoporosis. Ann Pharmacother 41:41-45
38. Strampel W, Emkey R, Civitelli R (2007) Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf 30:755-763
39. Rosen CJ (2005) Clinical practice. Postmenopausal osteoporosis. N Engl J Med 353:595-603
40. Diel IJ, Bergner R, Grotz KA (2007) Adverse effects of bisphosphonates: current issues. J Support Oncol 5:475-482